A Raman spectroscopic study on the hydrogen\|bond defect of water in 2\|hydroxyethyl (meth)acrylate hydrogels crosslinked by ethylene glycol dimethacrylate (EGDMA) and polyethylene glycol dimethacrylates were undertak...A Raman spectroscopic study on the hydrogen\|bond defect of water in 2\|hydroxyethyl (meth)acrylate hydrogels crosslinked by ethylene glycol dimethacrylate (EGDMA) and polyethylene glycol dimethacrylates were undertaken.It was found that PEGDMA 16 possessed a different behavior on the hydrogen\|bond defect from EGDMA and PEGDMA 9.That is,the extents of hydrogen\|bond defect for EGDMA and PEGDMA 9 decreased with the increase of crosslinking density,whereas for PEGDMA 16,as the crosslinking density is bigger than a certain value,the hydrogenbond defect is increased with the increase of crosslinking density.This is caused by the weaker effect of —CH 2OCH 2— in the PEGDMA 16 to the hydrogen\|bond defect of water than that of —OH in HEA and HEMA.展开更多
Novel physically cross-linked hydrogels, composed of PVA and hydroxy-terminated polyamidoamine(PAMAM) dendrimer G6-OH, were prepared by cyclic freezing/thawing treatment of aqueous solutions containing PVA and G6-OH. ...Novel physically cross-linked hydrogels, composed of PVA and hydroxy-terminated polyamidoamine(PAMAM) dendrimer G6-OH, were prepared by cyclic freezing/thawing treatment of aqueous solutions containing PVA and G6-OH. FTIR analysis indicates that PAMAM dendrimer G6-OH was successfully introduced into PVA hydrogels. Higher contents of G6-OH in PVA/G6-OH hydrogels resulted in higher swelling ratios, and faster reswelling rates. With the increase of freezing/thawing cyclic times, the swelling ratios and reswelling rates of PVA/G6-OH hydrogels decreased, which is similar to that of physically cross-linked PVA hydrogel.展开更多
背景:聚甲基丙烯酸-2-羟乙酯载药生物材料既有优异的生物学功能,又能释放药物,是一种潜在的组织工程支架材料和缓、控释药物载体材料。目的:观察布洛芬-聚甲基丙烯酸-2-羟乙酯水凝胶膜表面形态、吸水膨胀性能及缓控释性能。设计、时间...背景:聚甲基丙烯酸-2-羟乙酯载药生物材料既有优异的生物学功能,又能释放药物,是一种潜在的组织工程支架材料和缓、控释药物载体材料。目的:观察布洛芬-聚甲基丙烯酸-2-羟乙酯水凝胶膜表面形态、吸水膨胀性能及缓控释性能。设计、时间及地点:体外观察实验,于2008-01/05在福建医科大学药学院药学综合实验室完成。材料:甲基丙烯酸-2-羟乙酯为Aldrich Chemical Company产品;布洛芬为山东新华制药股份有限公司产品;过硫酸铵为广东省化学试剂工程技术研究开发中心产品;N-N’-亚甲基双丙烯酰胺为苏州市化工研究所有限公司产品。方法:选甲基丙烯酸-2-羟乙酯为单体、过硫酸铵为引发剂、N-N’-亚甲基双丙烯酰胺为交联剂、布洛芬为模型药物水相聚合,通过分步法和同步法导入药物。主要观察指标:光学显微镜和扫描电镜观察凝胶膜的表面形态;水溶液法测定凝胶膜的膨胀性能,拟体液环境中测定凝胶膜的释药特征。结果:含有N-N’-亚甲基双丙烯酰胺的水凝胶膜表面褶皱和沟痕更少,整体面光滑。随着交联剂加入量增加,吸水溶胀度减小,水凝胶膜形成体型结构的趋势增大。不论是同步法还是分步法所制的载药水凝胶膜,其释药达到平台的时间都比未加入交联剂的凝胶膜要长,但同时也发现在交联剂加入后,膜的载药量在减少,综合各因素以N-N’-亚甲基双丙烯酰胺含量7.5g/L为较佳方案。结论:水凝胶膜表面形态理想,导入药物后的载药膜具有良好的膨胀性能和更优秀的缓、控释特征。展开更多
文摘A Raman spectroscopic study on the hydrogen\|bond defect of water in 2\|hydroxyethyl (meth)acrylate hydrogels crosslinked by ethylene glycol dimethacrylate (EGDMA) and polyethylene glycol dimethacrylates were undertaken.It was found that PEGDMA 16 possessed a different behavior on the hydrogen\|bond defect from EGDMA and PEGDMA 9.That is,the extents of hydrogen\|bond defect for EGDMA and PEGDMA 9 decreased with the increase of crosslinking density,whereas for PEGDMA 16,as the crosslinking density is bigger than a certain value,the hydrogenbond defect is increased with the increase of crosslinking density.This is caused by the weaker effect of —CH 2OCH 2— in the PEGDMA 16 to the hydrogen\|bond defect of water than that of —OH in HEA and HEMA.
文摘Novel physically cross-linked hydrogels, composed of PVA and hydroxy-terminated polyamidoamine(PAMAM) dendrimer G6-OH, were prepared by cyclic freezing/thawing treatment of aqueous solutions containing PVA and G6-OH. FTIR analysis indicates that PAMAM dendrimer G6-OH was successfully introduced into PVA hydrogels. Higher contents of G6-OH in PVA/G6-OH hydrogels resulted in higher swelling ratios, and faster reswelling rates. With the increase of freezing/thawing cyclic times, the swelling ratios and reswelling rates of PVA/G6-OH hydrogels decreased, which is similar to that of physically cross-linked PVA hydrogel.
文摘背景:聚甲基丙烯酸-2-羟乙酯载药生物材料既有优异的生物学功能,又能释放药物,是一种潜在的组织工程支架材料和缓、控释药物载体材料。目的:观察布洛芬-聚甲基丙烯酸-2-羟乙酯水凝胶膜表面形态、吸水膨胀性能及缓控释性能。设计、时间及地点:体外观察实验,于2008-01/05在福建医科大学药学院药学综合实验室完成。材料:甲基丙烯酸-2-羟乙酯为Aldrich Chemical Company产品;布洛芬为山东新华制药股份有限公司产品;过硫酸铵为广东省化学试剂工程技术研究开发中心产品;N-N’-亚甲基双丙烯酰胺为苏州市化工研究所有限公司产品。方法:选甲基丙烯酸-2-羟乙酯为单体、过硫酸铵为引发剂、N-N’-亚甲基双丙烯酰胺为交联剂、布洛芬为模型药物水相聚合,通过分步法和同步法导入药物。主要观察指标:光学显微镜和扫描电镜观察凝胶膜的表面形态;水溶液法测定凝胶膜的膨胀性能,拟体液环境中测定凝胶膜的释药特征。结果:含有N-N’-亚甲基双丙烯酰胺的水凝胶膜表面褶皱和沟痕更少,整体面光滑。随着交联剂加入量增加,吸水溶胀度减小,水凝胶膜形成体型结构的趋势增大。不论是同步法还是分步法所制的载药水凝胶膜,其释药达到平台的时间都比未加入交联剂的凝胶膜要长,但同时也发现在交联剂加入后,膜的载药量在减少,综合各因素以N-N’-亚甲基双丙烯酰胺含量7.5g/L为较佳方案。结论:水凝胶膜表面形态理想,导入药物后的载药膜具有良好的膨胀性能和更优秀的缓、控释特征。
